FY2025 Earnings Forecast for CMPS Issued By Lifesci Capital

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Analysts at Lifesci Capital issued their FY2025 EPS estimates for COMPASS Pathways in a note issued to investors on Thursday, February 12th. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($1.66) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for COMPASS Pathways’ Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.84) EPS.

Several other equities analysts have also commented on the company. Compass Point set a $15.00 price target on COMPASS Pathways in a research note on Thursday, February 12th. Royal Bank Of Canada upped their target price on shares of COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Morgan Stanley lifted their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.11.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $7.63 on Monday. The company’s 50-day moving average is $6.77 and its two-hundred day moving average is $5.89. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.80. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a market capitalization of $732.63 million, a price-to-earnings ratio of -2.81 and a beta of 1.92.

Institutional Trading of COMPASS Pathways

A number of large investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth $38,000. Advisory Services Network LLC purchased a new stake in COMPASS Pathways during the 3rd quarter worth about $41,000. BIT Capital GmbH acquired a new position in COMPASS Pathways in the third quarter valued at approximately $54,000. MML Investors Services LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth approximately $69,000. Finally, Magnetar Financial LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $91,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways News Roundup

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.